Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis Global Blood Plasma Market. The report analyses the Blood Plasma Market By Type (Immunoglobulins- IV+SC, Albumin, Factor VIII- Plasma Derived, and Others), By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S, Canada, Germany, France, Italy, China, Japan, India, Australia, and South-East Asia). The report on Blood Plasma assesses the market for the actual period of 2013-2017 and the forecast period of 2018-2023.
According to Azoth Analytics research report "Global Blood Plasma Market - Analysis By Type (Immunoglobulins - IV+SC, Albumin, Factor VIII - Plasma Derived), By Region, By Country (2018 Edition): Opportunities and Forecast (2013-2023)", the global blood plasma market is projected to display a robust growth represented by a CAGR of 10.18% during 2018 - 2023.
The Blood Plasma market witness a substantial growth at a noteworthy rate over the past few years and anticipated to grow on the back of its increasing usage in plasma-derived medical products. In addition, rise in awareness towards plasma donation, rise of China blood plasma industry, introduction of new and specialized products, rising geriatric population, rapid increase of the healthcare expenditure on the diseases such as immunodeficiency, neurological disorders, clotting disabilities etc. anticipated to boost the market growth in future. Amongst the regions, North America accounts for the largest regional share in the global blood plasma market. Key factor driving the robust growth rate in North America region is collection of source plasma in large volume for the fractionation process.
The report titled "Global Blood Plasma Market - Analysis By Type (Immunoglobulins - IV+SC, Albumin, Factor VIII - Plasma Derived), By Region, By Country (2018 Edition): Opportunities and Forecast (2013-2023)" has covered and analysed the potential of Global Blood Plasma Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global blood ingredients market. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global Blood Plasma Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Blood Plasma Market - Size, Growth, Forecast
• Analysis By Type- Size, Volume, Growth, Forecast
o Immunoglobulin (IV+SC)
o Albumin
o Factor VIII (Plasma Derived)
Regional Markets - North America, Europe, Asia Pacific, and Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Blood Plasma Market - Size, Growth, Forecast
• Analysis By Type
o Immunoglobulin (IV+SC)
o Albumin
o Factor VIII (Plasma Derived)
Country Analysis - U.S., Canada, Germany, France, Italy, China, Japan, India, Australia, and South-East Asia. (Actual Period: 2013-2017, Forecast Period: 2018-2023)
• Blood Plasma Market - Size, Growth, Forecast
• Analysis By Type
o Immunoglobulin (IV+SC)
o Albumin
o Factor VIII (Plasma Derived)
Other Report Highlights
• Market Dynamics - Drivers and Restraints
• Market Trends
• Porter Five Forces Analysis
• Company Analysis - CSL Limited, Baxter International, Grifols S.A, Octa Pharma, Emergent Bio-solutions, Antaris Pharma, AMAG Pharma, Biota Pharma, Bio delivery Science International, Biotest A.G.
Customization of the Report
The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.